TABLE OF CONTENTS
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 RESEARCH METHODOLOGY
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7 DBMR MARKET POSITION GRID
2.8 DBMR MARKET CHALLENGE MATRIX
2.9 DBMR VENDOR SHARE ANALYSIS
2.10 MULTIVARIATE MODELLING
2.11 PRODUCT TIME LINE
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.1.1 INCREASING CASES OF LUNG CANCER
3.1.2 GROWING NUMBER OF SMOKERS
3.1.3 GOVERNMENT/ORGANIZATIONS FUNDING FOR THE R&D OF NEW DRUGS
3.1.4 INCREASING AWARENESS
3.1.5 STRATEGIC INITIATIVES OF THE COMPANIES
3.2 RESTRAINS
3.2.1 PRICING PRESSURE
3.2.2 HIGH COST
3.3 OPPORTUNITIES
3.3.1 APPROVALS AND PRODUCT PIPEPLINE
3.3.2 HEALTH TOURISM
3.3.3 NEW PRODUCT LAUNCHES
?
3.4 CHALLENGES
3.4.1 SIDE EFFECTS
3.4.2 LACK OF NUMBER OF ONCOLOGISTS
3.4.3 UNMET MEDICAL NEEDS
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
6 EPIDEMIOLOGY OF LUNG CANCER
7 REGULATORY PROCEDURE
8 PIPELINE DRUGS
9 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE
9.1 OVERVIEW
9.2 NON-SMALL CELL LUNG CANCER
9.2.1 SQUAMOUS CELL CARCINOMA
9.2.2 PULMONARY ADENOCARCINOMA
9.2.3 ADENOSQUAMOUS CARCINOMA (ASC)
9.2.4 LARGE CELL CARCINOMA
9.2.5 SARCOMATOID CARCINOMA
9.2.6 UNDIFFERENTIATED NON-SMALL CELL LUNG CANCER
9.2.7 SALIVARY GLAND-TYPE LUNG CARCINOMA
9.2.7.1 ADENOID CYSTIC CARCINOMA
9.2.7.2 MUCOEPIDERMOID CARCINOMA
9.2.7.3 ACINIC CELL CARCINOMA
9.2.7.4 EPITHELIAL-MYOEPITHELIAL CARCINOMA
9.2.7.5 GRANULAR CELL LUNG TUMORS
9.3 METASTATIC LUNG CANCER
9.4 MESOTHELIOMA
9.5 CHEST WALL TUMORS
9.5.1 PRIMARY TUMORS
9.5.2 METASTATIC TUMORS
9.5.3 SARCOMAS
9.6 PULMONARY NEUROENDOCRINE TUMORS
9.6.1 CARCINOID TUMORS
9.6.1.1 TYPICAL CARCINOID TUMORS
9.6.1.2 ATYPICAL CARCINOID TUMORS
9.6.2 LARGE CELL NEUROENDOCRINE LUNGS CARCINOMA
9.6.3 SMALL-CELL LUNG CANCER
9.6.3.1 SMALL CELL CARCINOMA
9.6.3.2 COMBINED SMALL CELL CARCINOMA
9.7 MEDIASTINAL TUMORS
9.7.1 GERM CELL TUMORS
9.7.2 LYMPHOMAS
9.7.3 THYMOMAS
10 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET, BY MOLECULE TYPE
10.1 OVERVIEW
10.2 SMALL MOLECULE
10.3 BILOGICS
11 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS
11.1 OVERVIEW
11.2 ALKYLATING AGENTS
11.3 ANTIMETABOLITES
11.4 MITOTIC INHIBITORS
11.5 MULTIKINASE INHIBITORS
11.6 EGFR INHIBITORS
11.7 OTHERS
12 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE
12.1 OVERVIEW
12.2 RADIATION THERAPY
12.2.1 EXTERNAL BEAM
12.2.2 BRACHYTHERAPY (INTERNAL OR IMPLANT RADIATION THERAPY)
12.2.3 STEREOTACTIC BODY RADIATION THERAPY (SBRT) / STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR)
12.2.4 STEREOTACTIC RADIOSURGERY (SRS)
12.3 CHEMOTHERAPY
12.3.1 CISPLATIN
12.3.2 PACLITAXEL (TAXOL)
12.3.3 VINORELBINE (NAVELBINE)
12.3.4 DOCETAXEL (TAXOTERE)
12.3.5 ALIMTA
12.3.6 GEMCITABINE (GEMZAR)
12.3.7 DURVALUMAB (IMFINZI)
12.3.8 OTHERS
12.4 TARGETED THERAPY
12.4.1 EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITORS
12.4.2 ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS
12.4.3 ANTI-ANGIOGENESIS THERAPY
12.4.4 MONOCLONAL ANTIBODIES
12.4.5 OTHERS
12.5 IMMUNOTHERAPY
12.5.1 ATEZOLIZUMAB (TECENTRIQ)
12.5.2 DURVALUMAB (IMFINZI)
12.5.3 NIVOLUMAB (OPDIVO)
12.5.4 PEMBROLIZUMAB (KEYTRUDA)
12.6 OTHERS
13 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET, BY THERAPY TYPE
13.1 OVERVIEW
13.2 SINGLE DRUG THERAPY
13.3 COMBINATION THERAPY
14 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITALS
14.3 SPECIALTY CLINICS
14.4 HOMECARE
14.5 OTHERS
15 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 HOSPITAL PHARMACY
15.3 RETAIL PHARMACY
15.4 ONLINE
15.5 OTHERS
?
16 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET, BY GEOGRAPHY
16.1 MIDDLE EAST AND AFRICA
16.1.1 SOUTH AFRICA
16.1.2 REST OF MIDDLE EAST AND AFRICA
16.1.3 EGYPT
16.1.4 SAUDI ARABIA
16.1.5 UNITED ARAB EMIRATES
16.1.6 ISRAEL
17 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET, COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA
18 COMPANY PROFILES
18.1 F. HOFFMANN-LA ROCHE LTD
18.1.1 COMPANY SNAPSHOT
18.1.2 REVENUE ANALYSIS
18.1.3 GEOGRAPHICAL PRESENCE
18.1.4 COMPANY SHARE ANALYSIS
18.1.5 PRODUCT PORTFOLIO
18.1.6 RECENT DEVELOPMENTS
18.2 MERCK & CO., INC.
18.2.1 COMPANY OVERVIEW
18.2.2 REVENUE ANALYSIS
18.2.3 GEOGRAPHICAL PRESENCE
18.2.4 COMPANY SHARE ANALYSIS
18.2.5 PRODUCT PORTFOLIO
18.2.6 RECENT DEVELOPMENTS
18.3 BRISTOL-MYERS SQUIBB COMPANY
18.3.1 COMPANY OVERVIEW
18.3.2 REVENUE ANALYSIS
18.3.3 GEOGRAPHICAL PRESENCE
18.3.4 COMPANY SHARE ANALYSIS
18.3.5 PRODUCT PORTFOLIO
18.3.6 RECENT DEVELOPMENTS
?
18.4 ASTRAZENECA
18.4.1 COMPANY SNAPSHOT
18.4.2 REVENUE ANALYSIS
18.4.3 GEOGRAPHICAL PRESENCE
18.4.4 COMPANY SHARE ANALYSIS
18.4.5 PRODUCT PORTFOLIO
18.4.6 RECENT DEVELOPMENTS
18.5 ELI LILLY AND COMPANY
18.5.1 COMPANY SNAPSHOT
18.5.2 REVENUE ANALYSIS
18.5.3 GEOGRAPHICAL PRESENCE
18.5.4 COMPANY SHARE ANALYSIS
18.5.5 PRODUCT PORTFOLIO
18.5.6 RECENT DEVELOPMENTS
18.6 ALLERGAN
18.6.1 COMPANY OVERVIEW
18.6.2 REVENUE ANALYSIS
18.6.3 GEOGRAPHICAL PRESENCE
18.6.4 PRODUCT PORTFOLIO
18.6.5 RECENT DEVELOPMENTS
18.7 AMGEN INC.
18.7.1 COMPANY OVERVIEW
18.7.2 REVENUE ANALYSIS
18.7.3 GEOGRAPHICAL PRESENCE
18.7.4 PRODUCT PORTFOLIO
18.7.5 RECENT DEVELOPMENTS
18.8 ASTELLAS PHARMA INC.
18.8.1 COMPANY OVERVIEW
18.8.2 REVENUE ANALYSIS
18.8.3 GEOGRAPHICAL PRESENCE
18.8.4 PRODUCT PORTFOLIO
18.8.5 RECENT DEVELOPMENTS
18.9 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
18.9.1 COMPANY OVERVIEW
18.9.2 REVENUE ANALYSIS
18.9.3 GEOGRAPHICAL PRESENCE
18.9.4 PRODUCT PORTFOLIO
18.9.5 RECENT DEVELOPMENTS
?
18.10 CELGENE CORPORATION
18.10.1 COMPANY OVERVIEW
18.10.2 REVENUE ANALYSIS
18.10.3 GEOGRAPHICAL PRESENCE
18.10.4 PRODUCT PORTFOLIO
18.10.5 RECENT DEVELOPMENTS
18.11 DR. REDDY'S LABORATORIES LTD.
18.11.1 COMPANY SNAPSHOT
18.11.2 REVENUE ANALYSIS
18.11.3 GEOGRAPHICAL PRESENCE
18.11.4 PRODUCT PORTFOLIO
18.11.5 RECENT DEVELOPMENTS
18.12 GLAXOSMITHKLINE PLC.
18.12.1 COMPANY OVERVIEW
18.12.2 REVENUE ANALYSIS
18.12.3 GEOGRAPHICAL PRESENCE
18.12.4 PRODUCT PORTFOLIO
18.12.5 RECENT DEVELOPMENTS
18.13 JOHNSON & JOHNSON SERVICES, INC.
18.13.1 COMPANY SNAPSHOT
18.13.2 REVENUE ANALYSIS
18.13.3 GEOGRAPHICAL PRESENCE
18.13.4 PRODUCT PORTFOLIO
18.13.5 RECENT DEVELOPMENTS
18.14 NOVARTIS AG
18.14.1 COMPANY SNAPSHOT
18.14.2 REVENUE ANALYSIS
18.14.3 GEOGRAPHICAL PRESENCE
18.14.4 PRODUCT PORTFOLIO
18.14.5 RECENT DEVELOPMENT
18.15 ONO PHARMACEUTICAL CO., LTD.
18.15.1 COMPANY OVERVIEW
18.15.2 REVENUE ANALYSIS
18.15.3 GEOGRAPHICAL PRESENCE
18.15.4 PRODUCT PORTFOLIO
18.15.5 RECENT DEVELOPMENTS
?
18.16 PFIZER INC.
18.16.1 COMPANY SNAPSHOT
18.16.2 RECENT FINANCIALS
18.16.3 GEOGRAPHICAL PRESENCE
18.16.4 PRODUCT PORTFOLIO
18.16.5 RECENT DEVELOPMENTS
18.17 SANOFI
18.17.1 COMPANY OVERVIEW
18.17.2 REVENUE ANALYSIS
18.17.3 GEOGRAPHICAL PRESENCE
18.17.4 PRODUCT PORTFOLIO
18.17.5 RECENT DEVELOPMENTS
18.18 SUMITOMO DAINIPPON PHARMA CO., LTD.
18.18.1 COMPANY OVERVIEW
18.18.2 REVENUE ANALYSIS
18.18.3 GEOGRAPHICAL PRESENCE
18.18.4 PRODUCT PORTFOLIO
18.18.5 RECENT DEVELOPMENTS
18.19 SUN PHARMACEUTICAL INDUSTRIES LTD.
18.19.1 COMPANY SNAPSHOT
18.19.2 REVENUE ANALYSIS
18.19.3 GEOGRAPHICAL PRESENCE
18.19.4 PRODUCT PORTFOLIO
18.19.5 RECENT DEVELOPMENTS
18.20 TAKEDA PHARMACEUTICAL COMPANY LIMITED
18.20.1 COMPANY OVERVIEW
18.20.2 REVENUE ANALYSIS
18.20.3 GEOGRAPHICAL PRESENCE
18.20.4 PRODUCT PORTFOLIO
18.20.5 RECENT DEVELOPMENTS
18.21 TEVA PHARMACEUTICAL INDUSTRIES LTD.
18.21.1 COMPANY OVERVIEW
18.21.2 REVENUE ANALYSIS
18.21.3 GEOGRAPHICAL PRESENCE
18.21.4 PRODUCT PORTFOLIO
18.21.5 RECENT DEVELOPMENTS
19 QUESTIONNAIRE
20 RELATED REPORTS
?
LIST OF TABLE